Oncoptpeptides - Bring hope through science

Bringing hope through science

Journey of innovation

Oncopeptides was formed in 2000 to develop anti-cancer drugs based on research by some of Sweden's leading cancer researchers and cancer research institutions. 
Read more


Annual Report 2020

“The past year was a transformational year for Oncopeptides  highlighted by the FDA´s priority review of our NDA submission, which paved the way for an accelerated approval in the U.S. in early 2021.”

Marty J Duvall, CEO


Click here to watch the film where CEO Marty J Duvall summarizes a transformational year.


Annual Report 2020 - online version


For further information, please contact:

Linda Holmström
Director of Investor Relations

Profile image

Press release -

Oncopeptides completes patient enrollment in phase 2 PORT study

Read press release
Events Oncopeptides

Upcoming events

View calendar

Oncopeptides vision

Vision of Oncopeptides

“Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Webinar Embassy of Sweden

Seminar at the Embassy of Sweden Washington DC

The Embassy of Sweden in Washington DC, Oncopeptides AB, Dana Farber and Uppsala University hosted a virtual seminar on February 2nd,“A Swedish American Journey of Cancer Research”. 

Read more

Cultures & Values

We are science and data driven, innovative and curious, making decisions based on systematic and thorough analyses.

Read more